







Home ► All Journals ► Expert Review of Clinical Pharmacology ► List of Issues ► Volume 5, Issue 5 ► Medicines for pediatric oncology: can we

Expert Review of Clinical Pharmacology > Volume 5, 2012 - Issue 5

43 | 11

1

Views CrossRef citations to date Altmetric

Editorial

Medicines for pediatric oncology: can we overcome the failure to deliver?

Agnes Saint-Raymond & Ralf Herold


Pages 493-495 | Published online: 10 Jan 2014

G Cite this article https://doi.org/10.1586/ecp.12.51

Sample our
Bioscience
Journals
>> Sign in here to start your access to the latest two volumes for 14 days



Figures & data





Metrics

➡ Reprints & Permissions

Read this article

We Care About Your Privacy

We and our 843 partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. Privacy Policy

Essential Onl

I Accept

We and our partners process data to provide:

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development.

List of Partners (vendors)

Show Purpose

Editorial

For reprint orders, please contact reprints@expert-reviews.com

Medicines for pediatric oncology: can we overcome the failure to deliver?

Expert Rev. Clin. Pharmacol. 5(5), 493-495 (2012)



Agnes
Saint-Raymond
Author for correspondence

Author for correspondence: European Medicines Agency, 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.: +44 207 523 7017 Fax: +44 207 523 7040 agnes saint-raymond® ema.europa.eu



Ralf Herold

European Medicines Agency 7 Westferry Circus, Canary Wharf, London E14 4HB, UK discussion by the Committee and may include revoking the condition waivers, giving back to the Committee the possibility to analyze the mechanism of action and target of the new medicines in order to eventually obtain the necessary data in children within a reasonable timeframe."

To date, children do not have access to pharmaceutical companies. This mean the medicines necessary to treat pediatric in practice that access to anticancer med

"The way forward regarding pediatric oncology is under

the medicines necessary to treat pediatric cancers. Pediatric tumors have different names and specificities from adult tumors that go far beyond the naming issue. In most other therapeutic areas, with the main exception in pediatric rheumatology, the diseases affecting children are close to those affecting adults with respect to type of diseases and pathophysiology. Owing to specific gene mutation and expression profiles and fast tumor growth, cancers affecting children are different. An aggravating factor for the lack of authorized medicines is the rarity of the diseases, representing a small market overall, although they are frequent among serious pediatric diseases. Cancer represents the second main cause of death in children and treatments place a heavy burden on the child and his or her family. The uncertainties on long-term prognosis owing to potential late relapses, as well as complications of chemotherapy and radiotherapy add to this burden. However, pediatric oncology is also the area where treatments have achieved outstanding results through rigorous proto-cols (using medicines off-label), resulting in long-term survival and cures [1].

Another paradox is that most of the treatments used today were established by academics and hospital pediatric oncologists over the last decades, generally with little help or interest from large pharmaceutical companies. This meant in practice that access to anticancer medicines was always significantly delayed for children [2] in contradiction with ethical principles and existing guidelines such as the International Conference on Harmonization guideline on the development of pediatric medicines (E11), which requires simultaneous submission for adults and children when the disease is serious or life threatening, when there are limited or no therapeutic alternatives [101].

In fact, behind the success lies another reality. If most of the success comes from effective treatments of acute pediatric leukemia and lymphoma, many other tumors – especially advanced stages and those of the CNS such as high-grade glioma – remain without effective therapeutic options, with short survival and devastating effects on the child and the family [3].

Regulatory initiatives in the USA, then in Europe, aim to ensure that medicines intended for adults are developed for children where there are unmet pediatric needs [102,103]. Unfortunately, to date in pediatric oncology these have not been so successful for several reasons. As part of the US Best Pharmaceutical for Children Act (BPCA), the US FDA can issue Written Requests based on public health needs describing how a company can develop a medicine for children, with the prospect of getting additional

Expert Reviews

KEYWORDS: child • development • medicines • oncology • regulation

Disclai

The view understo

Financ


The author entity material

×

be fic

organization ter or ncies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.



Recommended articles

Cited by 11

Information for

Authors

R&D professionals

Editors

Librarians

Societies

Opportunities

Reprints and e-prints

Advertising solutions

Accelerated publication

Corporate access solutions

Open access

Overview

Open journals

Open Select

Dove Medical Press

F1000Research

Help and information

Help and contact

Newsroom

All iournals

Books

Keep up to date

Register to receive personalised research and resources



Ciar











Registered 5 Howick P ×

or & Francis Group